Literature DB >> 22925131

Lys66 residue as a determinant of high mismatch extension and misinsertion rates of HIV-1 reverse transcriptase.

Chisanga Lwatula1, Scott J Garforth, Vinayaka R Prasad.   

Abstract

A major factor contributing to the high mutation rate of HIV-1 reverse transcriptase (RT) is its high propensity for misincorporation. Misincorporation requires both deoxyribonucleotide triphosphate (dNTP) misinsertion and the subsequent extension of the mismatched terminus thus formed. We hypothesized that Lys66 is a determinant of mismatch extension based on its position near the primer terminus. This hypothesis was tested by steady-state kinetic studies using wild-type HIV-1 RT and four Lys66 substitution mutants: Lys66Arg, Lys66Ala, Lys66Asn and Lys66Thr. The mismatch extension efficiency was reduced for all mutants, with Lys66Ala, Lys66Asn and Lys66Thr showing a four- to six-fold reduction compared with wild-type HIV-1 RT. Surprisingly, the nonconservative substitutions also led to large decreases in misinsertion efficiency, ranging from as low as three-fold to values much higher than 23-fold. Thus, the Lys66Arg mutant was akin to wild-type HIV-1 RT, whereas all nonconservative mutants displayed significantly decreased efficiency for both events. Our results suggest that Lys66, much like Lys65, is a determinant of both dNTP misinsertion and mismatch extension efficiency. While Lys65 is known to contact the γ-phosphate of incoming dNTP, the Lys66 side chain is in the vicinity of the primer terminus. However, our results suggest that both residues have a similar influence on dNTP misinsertion and mispair extension efficiencies of HIV-1 RT. When we tested the mutants for susceptibility to selected nucleoside analog and non-nucleoside analog drugs, similarly to Lys65Arg, the Lys66Ala and Lys66Asn mutants displayed mild resistance to the nucleoside analog drug 3'-azido-3'-deoxythymidine-5'-triphosphate (AZTTP).
© 2012 The Authors Journal compilation © 2012 FEBS.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22925131      PMCID: PMC3472125          DOI: 10.1111/j.1742-4658.2012.08807.x

Source DB:  PubMed          Journal:  FEBS J        ISSN: 1742-464X            Impact factor:   5.542


  48 in total

1.  UCSF Chimera--a visualization system for exploratory research and analysis.

Authors:  Eric F Pettersen; Thomas D Goddard; Conrad C Huang; Gregory S Couch; Daniel M Greenblatt; Elaine C Meng; Thomas E Ferrin
Journal:  J Comput Chem       Date:  2004-10       Impact factor: 3.376

2.  The accuracy of reverse transcriptase from HIV-1.

Authors:  J D Roberts; K Bebenek; T A Kunkel
Journal:  Science       Date:  1988-11-25       Impact factor: 47.728

3.  Fidelity of HIV-1 reverse transcriptase.

Authors:  B D Preston; B J Poiesz; L A Loeb
Journal:  Science       Date:  1988-11-25       Impact factor: 47.728

4.  Selective excision of AZTMP by drug-resistant human immunodeficiency virus reverse transcriptase.

Authors:  P L Boyer; S G Sarafianos; E Arnold; S H Hughes
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

5.  Molecular mechanisms of resistance to human immunodeficiency virus type 1 with reverse transcriptase mutations K65R and K65R+M184V and their effects on enzyme function and viral replication capacity.

Authors:  Kirsten L White; Nicolas A Margot; Terri Wrin; Christos J Petropoulos; Michael D Miller; Lisa K Naeger
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

6.  A mutation in the primer grip region of HIV-1 reverse transcriptase that confers reduced fidelity of DNA synthesis.

Authors:  M Gutiérrez-Rivas; L Menéndez-Arias
Journal:  Nucleic Acids Res       Date:  2001-12-15       Impact factor: 16.971

7.  Structures of HIV-1 reverse transcriptase with pre- and post-translocation AZTMP-terminated DNA.

Authors:  Stefan G Sarafianos; Arthur D Clark; Kalyan Das; Steve Tuske; Jens J Birktoft; Palanichamy Ilankumaran; Andagar R Ramesha; Jane M Sayer; Donald M Jerina; Paul L Boyer; Stephen H Hughes; Eddy Arnold
Journal:  EMBO J       Date:  2002-12-02       Impact factor: 11.598

8.  Genotypic and phenotypic analyses of HIV-1 in antiretroviral-experienced patients treated with tenofovir DF.

Authors:  Nicolas A Margot; Erica Isaacson; Ian McGowan; Andrew K Cheng; Robert T Schooley; Michael D Miller
Journal:  AIDS       Date:  2002-06-14       Impact factor: 4.177

9.  Structures of HIV-1 RT-DNA complexes before and after incorporation of the anti-AIDS drug tenofovir.

Authors:  Steve Tuske; Stefan G Sarafianos; Arthur D Clark; Jianping Ding; Lisa K Naeger; Kirsten L White; Michael D Miller; Craig S Gibbs; Paul L Boyer; Patrick Clark; Gang Wang; Barbara L Gaffney; Roger A Jones; Donald M Jerina; Stephen H Hughes; Eddy Arnold
Journal:  Nat Struct Mol Biol       Date:  2004-04-25       Impact factor: 15.369

10.  Human immunodeficiency virus reverse transcriptase and protease sequence database.

Authors:  Soo-Yon Rhee; Matthew J Gonzales; Rami Kantor; Bradley J Betts; Jaideep Ravela; Robert W Shafer
Journal:  Nucleic Acids Res       Date:  2003-01-01       Impact factor: 16.971

View more
  3 in total

1.  Resolution of Specific Nucleotide Mismatches by Wild-Type and AZT-Resistant Reverse Transcriptases during HIV-1 Replication.

Authors:  Siarhei Kharytonchyk; Steven R King; Clement B Ndongmo; Krista L Stilger; Wenfeng An; Alice Telesnitsky
Journal:  J Mol Biol       Date:  2016-04-10       Impact factor: 5.469

Review 2.  The lysine 65 residue in HIV-1 reverse transcriptase function and in nucleoside analog drug resistance.

Authors:  Scott J Garforth; Chisanga Lwatula; Vinayaka R Prasad
Journal:  Viruses       Date:  2014-10-23       Impact factor: 5.048

Review 3.  Mechanistic Interplay between HIV-1 Reverse Transcriptase Enzyme Kinetics and Host SAMHD1 Protein: Viral Myeloid-Cell Tropism and Genomic Mutagenesis.

Authors:  Nicole E Bowen; Adrian Oo; Baek Kim
Journal:  Viruses       Date:  2022-07-26       Impact factor: 5.818

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.